

Giovanni Tripepi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11749360/publications.pdf>

Version: 2024-02-01

191
papers

14,519
citations

19657

61
h-index

20358

116
g-index

191
all docs

191
docs citations

191
times ranked

11521
citing authors

#	ARTICLE	IF	CITATIONS
1	Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. <i>Lancet, The</i> , 2001, 358, 2113-2117.	13.7	993
2	Asymmetric dimethyl-arginine (ADMA) response to inflammation in acute infections. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 801-806.	0.7	592
3	Adiponectin, Metabolic Risk Factors, and Cardiovascular Events among Patients with End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 134-141.	6.1	560
4	Plasma Norepinephrine Predicts Survival and Incident Cardiovascular Events in Patients With End-Stage Renal Disease. <i>Circulation</i> , 2002, 105, 1354-1359.	1.6	485
5	Vitamin D levels and patient outcome in chronic kidney disease. <i>Kidney International</i> , 2009, 75, 88-95.	5.2	384
6	Asymmetrical Dimethylarginine Predicts Progression to Dialysis and Death in Patients with Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2449-2455.	6.1	352
7	Sample size calculations: basic principles and common pitfalls. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1388-1393.	0.7	302
8	Left ventricular mass monitoring in the follow-up of dialysis patients: Prognostic value of left ventricular hypertrophy progression. <i>Kidney International</i> , 2004, 65, 1492-1498.	5.2	299
9	Chronic Fluid Overload and Mortality in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 2491-2497.	6.1	286
10	Abdominal Obesity and All-Cause and Cardiovascular Mortality in End-Stage Renal Disease. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1265-1272.	2.8	279
11	Exercise in Patients on Dialysis: A Multicenter, Randomized Clinical Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1259-1268.	6.1	272
12	Cardiac Natriuretic Peptides Are Related to Left Ventricular Mass and Function and Predict Mortality in Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 1508-1515.	6.1	270
13	Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. <i>Kidney International</i> , 2002, 61, 609-614.	5.2	247
14	Prognostic Impact of the Indexation of Left Ventricular Mass in Patients Undergoing Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2768-2774.	6.1	246
15	Asymmetric Dimethylarginine, C-Reactive Protein, and Carotid Intima-Media Thickness in End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 490-496.	6.1	235
16	Detection of Pulmonary Congestion by Chest Ultrasound in Dialysis Patients. <i>JACC: Cardiovascular Imaging</i> , 2010, 3, 586-594.	5.3	232
17	Pulmonary Congestion Predicts Cardiac Events and Mortality in ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 639-646.	6.1	221
18	Inflammation Markers, Adhesion Molecules, and All-Cause and Cardiovascular Mortality in Patients with ESRD. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, S83-S88.	6.1	217

#	ARTICLE	IF	CITATIONS
19	Left ventricular hypertrophy, cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. <i>Kidney International</i> , 2002, 62, 339-345.	5.2	194
20	Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition. <i>Journal of the American Society of Nephrology: JASN</i> , 2011, 22, 1923-1930.	6.1	190
21	Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 1459-1464.	0.7	181
22	Prognostic Value of Echocardiographic Indicators of Left Ventricular Systolic Function in Asymptomatic Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1029-1037.	6.1	180
23	Inflammation is associated with carotid atherosclerosis in dialysis patients. <i>Journal of Hypertension</i> , 2000, 18, 1207-1213.	0.5	179
24	Inflammation and outcome in end-stage renal failure: Does female gender constitute a survival advantage?. <i>Kidney International</i> , 2002, 62, 1791-1798.	5.2	175
25	Traditional and emerging cardiovascular risk factors in end-stage renal disease. <i>Kidney International</i> , 2003, 63, S105-S110.	5.2	168
26	Prognostic Value of Ultrasonographic Measurement of Carotid Intima Media Thickness in Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2458-2464.	6.1	166
27	Diagnostic potential of cardiac natriuretic peptides in dialysis patients. <i>Kidney International</i> , 2001, 59, 1559-1566.	5.2	145
28	Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2002, 40, 68-75.	1.9	144
29	Low Triiodothyronine. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 2789-2795.	6.1	132
30	The Agreement between Auscultation and Lung Ultrasound in Hemodialysis Patients: The LUST Study. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 2005-2011.	4.5	124
31	Norepinephrine and Concentric Hypertrophy in Patients With End-Stage Renal Disease. <i>Hypertension</i> , 2002, 40, 41-46.	2.7	123
32	Vitamin K, vertebral fractures, vascular calcifications, and mortality: Vitamin K Italian (VIKI) dialysis study. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 2271-2278.	2.8	122
33	Nocturnal Hypoxemia Predicts Incident Cardiovascular Complications in Dialysis Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 729-733.	6.1	122
34	Autonomic neuropathy is linked to nocturnal hypoxaemia and to concentric hypertrophy and remodelling in dialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2001, 16, 70-77.	0.7	121
35	Nocturnal hypoxemia, night-day arterial pressure changes and left ventricular geometry in dialysis patients. <i>Kidney International</i> , 1998, 53, 1078-1084.	5.2	120
36	Novel Cardiovascular Risk Factors in End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, S77-S80.	6.1	120

#	ARTICLE	IF	CITATIONS
37	ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria. Journal of the American Society of Nephrology: JASN, 2011, 22, 1122-1128.	6.1	119
38	Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardial pathology in patients with ESRD. Kidney International, 2005, 67, 2330-2337.	5.2	116
39	Prognostic value of 24-hour ambulatory blood pressure monitoring and of night/day ratio in nondiabetic, cardiovascular events-free hemodialysis patients. Kidney International, 2005, 68, 1294-1302.	5.2	114
40	Adiponectin is markedly increased in patients with nephrotic syndrome and is related to metabolic risk factors. Kidney International, 2003, 63, S98-S102.	5.2	110
41	Paricalcitol and Endothelial Function in Chronic Kidney Disease Trial. Hypertension, 2014, 64, 1005-1011.	2.7	106
42	Renal Biopsy in 2015 - From Epidemiology to Evidence-Based Indications. American Journal of Nephrology, 2016, 43, 1-19.	3.1	106
43	Dissecting Inflammation in ESRD: Do Cytokines and C-Reactive Protein Have a Complementary Prognostic Value for Mortality in Dialysis Patients?. Journal of the American Society of Nephrology: JASN, 2006, 17, S169-S173.	6.1	101
44	Intention to treat and per protocol analysis in clinical trials. Nephrology, 2020, 25, 513-517.	1.6	101
45	Inflammation and Asymmetric Dimethylarginine for Predicting Death and Cardiovascular Events in ESRD Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1714-1721.	4.5	98
46	Endothelial Dysfunction and Mild Renal Insufficiency in Essential Hypertension. Circulation, 2004, 110, 821-825.	1.6	94
47	Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation, 2006, 22, 538-544.	0.7	94
48	Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2004, 15, 435-441.	6.1	93
49	Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients. Journal of Hypertension, 1999, 17, 1751-1758.	0.5	92
50	Left atrial volume in end-stage renal disease: a prospective cohort study. Journal of Hypertension, 2006, 24, 1173-1180.	0.5	90
51	Analysis of risk factors associated with renal function trajectory over time: a comparison of different statistical approaches. Nephrology Dialysis Transplantation, 2015, 30, 1237-1243.	0.7	81
52	Left Atrial Volume Monitoring and Cardiovascular Risk in Patients with End-Stage Renal Disease. Journal of the American Society of Nephrology: JASN, 2007, 18, 1316-1322.	6.1	78
53	Inflammation and Atherosclerosis in End-Stage Renal Disease. Blood Purification, 2003, 21, 29-36.	1.8	76
54	Predictors of Cardiovascular Death in ESRD. Seminars in Nephrology, 2005, 25, 358-362.	1.6	76

#	ARTICLE	IF	CITATIONS
55	Phosphate attenuates the anti-proteinuric effect of very low-protein diet in CKD patients. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 632-640.	0.7	73
56	Adipose tissue as a source of inflammatory cytokines in health and disease: Focus on end-stage renal disease. <i>Kidney International</i> , 2003, 63, S65-S68.	5.2	72
57	Physical Performance and Clinical Outcomes in Dialysis Patients: A Secondary Analysis of the Excite Trial. <i>Kidney and Blood Pressure Research</i> , 2014, 39, 205-211.	2.0	72
58	Sleep Apnea in Renal Patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2001, 12, 2854-2859.	6.1	72
59	Statistical methods for the assessment of prognostic biomarkers (Part I): Discrimination. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1399-1401.	0.7	68
60	Diagnostic value of troponin T for alterations in left ventricular mass and function in dialysis patients. <i>Kidney International</i> , 2002, 62, 1884-1890.	5.2	66
61	Long-term visit-to-visit office blood pressure variability increases the risk of adverse cardiovascular outcomes in patients with chronic kidney disease. <i>Kidney International</i> , 2013, 84, 381-389.	5.2	65
62	Association of IL-6 and a Functional Polymorphism in the IL-6 Gene with Cardiovascular Events in Patients with CKD. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 232-240.	4.5	64
63	Inflammatory proteins as predictors of cardiovascular disease in patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2004, 19, v67-v72.	0.7	62
64	Vitamin K and Osteoporosis. <i>Nutrients</i> , 2020, 12, 3625.	4.1	62
65	Prevalence of Vertebral Fractures, Vascular Calcifications, and Mortality in Warfarin Treated Hemodialysis Patients. <i>Current Vascular Pharmacology</i> , 2015, 13, 248-258.	1.7	62
66	Methylarginines and mortality in patients with end stage renal disease: A prospective cohort study. <i>Atherosclerosis</i> , 2009, 207, 541-545.	0.8	60
67	Diagnostic methods 2: receiver operating characteristic (ROC) curves. <i>Kidney International</i> , 2009, 76, 252-256.	5.2	60
68	Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. <i>Kidney International</i> , 2010, 77, 225-231.	5.2	60
69	Efficacy of a remote web-based lung ultrasound training for nephrologists and cardiologists: a LUST trial sub-project. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1982-1988.	0.7	60
70	Vitamin D receptor (VDR) gene polymorphism is associated with left ventricular (LV) mass and predicts left ventricular hypertrophy (LVH) progression in end-stage renal disease (ESRD) patients. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 313-319.	2.8	59
71	Effect of a home based, low intensity, physical exercise program in older adults dialysis patients: a secondary analysis of the EXCITE trial. <i>BMC Geriatrics</i> , 2018, 18, 248.	2.7	59
72	Hepatocyte growth factor predicts survival and relates to inflammation and intima media thickness in end-stage renal disease. <i>American Journal of Kidney Diseases</i> , 2000, 36, 945-952.	1.9	56

#	ARTICLE	IF	CITATIONS
73	Assessment of obesity in chronic kidney disease. <i>Current Opinion in Nephrology and Hypertension</i> , 2012, 21, 641-646.	2.0	56
74	Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. <i>Journal of Hypertension</i> , 2006, 24, 2039-2046.	0.5	55
75	Left ventricular hypertrophy and nocturnal hypoxemia in hemodialysis patients. <i>Journal of Hypertension</i> , 2001, 19, 287-293.	0.5	52
76	Asymptomatic Pulmonary Congestion and Physical Functioning in Hemodialysis Patients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 1343-1348.	4.5	50
77	Biomarkers of Left Atrial Volume. <i>Hypertension</i> , 2009, 54, 818-824.	2.7	49
78	Physical activity in chronic kidney disease and the EXerCise Introduction To Enhance trial. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, ii18-ii22.	0.7	49
79	Prospective Study of Neuropeptide Y as an Adverse Cardiovascular Risk Factor in End-Stage Renal Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2611-2617.	6.1	48
80	Left Ventricular Systolic Function Monitoring in Asymptomatic Dialysis Patients: A Prospective Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 1460-1465.	6.1	48
81	Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2004, 43, 479-484.	1.9	47
82	Sleep quality in patients with chronic renal failure: A 3-year longitudinal study. <i>Sleep Medicine</i> , 2008, 9, 240-246.	1.6	47
83	Sympathetic Nerve Traffic and Asymmetric Dimethylarginine in Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2620-2627.	4.5	46
84	Adipose tissue cytokines, insulin sensitivity, inflammation, and cardiovascular outcomes in end-stage renal disease patients. , 2005, 15, 125-130.		45
85	Testing for causality and prognosis: etiological and prognostic models. <i>Kidney International</i> , 2008, 74, 1512-1515.	5.2	45
86	Effect of Renal Artery Stenting on Left Ventricular Mass: A Randomized Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2012, 60, 39-46.	1.9	45
87	A randomized multicenter trial on a lung ultrasoundâ€‘guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk. <i>Kidney International</i> , 2021, 100, 1325-1333.	5.2	45
88	Mendelian Randomization: A New Approach to Studying Epidemiology in ESRD. <i>American Journal of Kidney Diseases</i> , 2006, 47, 332-341.	1.9	43
89	Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 2005, 45, 702-707.	1.9	42
90	High Prevalence of Vertebral Fractures Assessed by Quantitative Morphometry in Hemodialysis Patients, Strongly Associated with Vascular Calcifications. <i>Calcified Tissue International</i> , 2013, 93, 39-47.	3.1	42

#	ARTICLE	IF	CITATIONS
91	Rate of Atherosclerotic Plaque Formation Predicts Cardiovascular Events in ESRD. Journal of the American Society of Nephrology: JASN, 2008, 19, 757-763.	6.1	41
92	Statistical methods for the assessment of prognostic biomarkers(part II): calibration and re-classification. Nephrology Dialysis Transplantation, 2010, 25, 1402-1405.	0.7	41
93	The Role of Deconditioning in the End-Stage Renal Disease Myopathy: Physical Exercise Improves Altered Resting Muscle Oxygen Consumption. American Journal of Nephrology, 2015, 41, 329-336.	3.1	41
94	Low vitamin K1 intake in haemodialysis patients. Clinical Nutrition, 2017, 36, 601-607.	5.0	40
95	Inflammation as a Mediator of the Link between Mild to Moderate Renal Insufficiency and Endothelial Dysfunction in Essential Hypertension. Journal of the American Society of Nephrology: JASN, 2006, 17, S64-S68.	6.1	39
96	Abdominal obesity modifies the risk of hypertriglyceridemia for all-cause and cardiovascular mortality in hemodialysis patients. Kidney International, 2011, 79, 765-772.	5.2	39
97	Blood Pressure Variability, Mortality, and Cardiovascular Outcomes in CKD Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 233-240.	4.5	39
98	HYPERTENSION IN HEMODIALYSIS PATIENTS: Cardiac Consequences of Hypertension in Hemodialysis Patients. Seminars in Dialysis, 2004, 17, 299-303.	1.3	38
99	Obesity and CKD progression: hard facts on fat CKD patients. Nephrology Dialysis Transplantation, 2013, 28, iv105-iv108.	0.7	36
100	Risk prediction models. Nephrology Dialysis Transplantation, 2013, 28, 1975-1980.	0.7	36
101	Prognostic value of the New York Heart Association classification in end-stage renal disease. Nephrology Dialysis Transplantation, 2007, 22, 1377-1382.	0.7	34
102	Serum Alkaline Phosphatase Negatively Affects Endothelium-Dependent Vasodilation in Na ⁺ ve Hypertensive Patients. Hypertension, 2015, 66, 874-880.	2.7	34
103	Searching for biomarker patterns characterizing carotid atherosclerotic burden in patients with reduced renal function. Nephrology Dialysis Transplantation, 2007, 22, 3521-3526.	0.7	32
104	Lung Congestion as a Risk Factor in End-Stage Renal Disease. Blood Purification, 2013, 36, 184-191.	1.8	32
105	Asymmetric dimethylarginine predicts survival in the elderly. Age, 2013, 35, 2465-2475.	3.0	31
106	Resistin and all-cause and cardiovascular mortality: effect modification by adiponectin in end-stage kidney disease patients. Nephrology Dialysis Transplantation, 2013, 28, iv181-iv187.	0.7	30
107	Moderator's view: Ambulatory blood pressure monitoring and home blood pressure for the prognosis, diagnosis and treatment of hypertension in dialysis patients. Nephrology Dialysis Transplantation, 2015, 30, 1443-1448.	0.7	30
108	Clinical Epidemiology of Major Nontraditional Risk Factors in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2005, 25, 84-87.	2.3	29

#	ARTICLE	IF	CITATIONS
109	An overview on standard statistical methods for assessing exposure-outcome link in survival analysis (Part II): the Kaplan-Meier analysis and the Cox regression method. <i>Aging Clinical and Experimental Research</i> , 2012, 24, 203-206.	2.9	29
110	Body mass index trend in haemodialysis patients: the shift of nutritional disorders in two Italian regions. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1699-1705.	0.7	29
111	Intact FGF23 and ß ₂ -microglobulin during acute inflammation/sepsis in CKD patients. <i>European Journal of Clinical Investigation</i> , 2016, 46, 234-241.	3.4	28
112	Hepatocyte Growth Factor and Left Ventricular Geometry in End-Stage Renal Disease. <i>Hypertension</i> , 2003, 41, 88-92.	2.7	27
113	The GLU298ASP variant of nitric oxide synthase interacts with asymmetric dimethyl arginine in determining cardiovascular mortality in patients with end-stage renal disease. <i>Journal of Hypertension</i> , 2005, 23, 1825-1830.	0.5	27
114	Kidney Function and Risk Factors for Left Ventricular Hypertrophy in Untreated Uncomplicated Essential Hypertension. <i>American Journal of Kidney Diseases</i> , 2008, 52, 74-84.	1.9	27
115	Nocturnal Hypertension and Altered Night-Time BP Profile and Atherosclerosis in Renal Transplant Patients. <i>Transplantation</i> , 2016, 100, 2211-2218.	1.0	27
116	Vascular endothelial growth factor, left ventricular dysfunction and mortality in hemodialysis patients. <i>Journal of Hypertension</i> , 2008, 26, 1875-1882.	0.5	24
117	Methods to Analyze Time-to-Event Data: The Cox Regression Analysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-6.	4.0	24
118	Neuropeptide Y, left ventricular mass and function in patients with end stage renal disease. <i>Journal of Hypertension</i> , 2003, 21, 1355-1362.	0.5	23
119	Pro-inflammatory cytokines and bone fractures in CKD patients. An exploratory single centre study. <i>BMC Nephrology</i> , 2012, 13, 134.	1.8	23
120	Office, standardized and 24-h ambulatory blood pressure and renal function loss in renal transplant patients. <i>Journal of Hypertension</i> , 2018, 36, 119-125.	0.5	23
121	Chlamydia pneumoniae, overall and cardiovascular mortality in end-stage renal disease (ESRD). <i>Kidney International</i> , 2003, 64, 579-584.	5.2	22
122	Urotensin II and Biomarkers of Endothelial Activation and Atherosclerosis in End-Stage Renal Disease. <i>American Journal of Hypertension</i> , 2006, 19, 505-510.	2.0	21
123	Competitive Interaction Between Fibroblast Growth Factor 23 And Asymmetric Dimethylarginine in Patients With CKD. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 935-944.	6.1	21
124	Calcimimetic and vitamin D analog use in hemodialyzed patients is associated with increased levels of vitamin K dependent proteins. <i>Endocrine</i> , 2016, 51, 333-341.	2.3	21
125	Subclinical pulmonary congestion is prevalent in nephrotic syndrome. <i>Kidney International</i> , 2016, 89, 421-428.	5.2	21
126	Nocturnal Hypoxemia: A Neglected Cardiovascular Risk Factor in End-Stage Renal Disease?. <i>Blood Purification</i> , 2002, 20, 120-123.	1.8	20

#	ARTICLE	IF	CITATIONS
127	Urotensin II and Cardiomyopathy in End-Stage Renal Disease. <i>Hypertension</i> , 2008, 51, 326-333.	2.7	19
128	Hypertension as a cardiovascular risk factor in end-stage renal failure. <i>Current Hypertension Reports</i> , 2002, 4, 381-386.	3.5	18
129	The E-selectin gene polymorphism and carotid atherosclerosis in end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1921-1926.	0.7	18
130	Neuropeptide Y and chronic kidney disease progression: a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1805-1812.	0.7	18
131	Methods to Analyse Time-to-Event Data: The Kaplan-Meier Survival Curve. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-7.	4.0	18
132	Insulin-resistance HCV infection-related affects vascular stiffness in normotensives. <i>Atherosclerosis</i> , 2015, 238, 108-112.	0.8	17
133	Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes mellitus. <i>Journal of Nephrology</i> , 2019, 32, 635-643.	2.0	16
134	The fat-mass and obesity-associated gene (FTO) predicts mortality in chronic kidney disease of various severity. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, iv58-iv62.	0.7	15
135	eNOS and Caveolin-1 Gene Polymorphisms Interaction and Intima Media Thickness: A Proof of Concept Study in ESRD Patients. <i>American Journal of Hypertension</i> , 2012, 25, 103-108.	2.0	15
136	Treatment-resistant hypertension in the hemodialysis population: a 44-h ambulatory blood pressure monitoring-based study. <i>Journal of Hypertension</i> , 2020, 38, 1849-1856.	0.5	15
137	Sevelamer Use, Vitamin K Levels, Vascular Calcifications, and Vertebral Fractures in Hemodialysis Patients: Results from the VIKI Study. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 500-509.	2.8	15
138	Can the assessment of ultrasound lung water in haemodialysis patients be simplified?. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2321-2326.	0.7	15
139	Atherosclerosis and the Glu298Asp Polymorphism of the eNOS Gene in White Patients With End-Stage Renal Disease. <i>American Journal of Hypertension</i> , 2005, 18, 1549-1555.	2.0	14
140	Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 523.	2.4	14
141	Traditional and nontraditional risk factors as predictors of cerebrovascular events in patients with end stage renal disease. <i>Journal of Hypertension</i> , 2010, 28, 2468-2474.	0.5	14
142	Reappraisal in two European cohorts of the prognostic power of left ventricular mass index in chronic kidney failure. <i>Kidney International</i> , 2017, 91, 704-710.	5.2	13
143	Prevalence of renal artery stenosis in patients undergoing cardiac catheterization. <i>Internal and Emergency Medicine</i> , 2013, 8, 401-408.	2.0	11
144	Asymmetric and Symmetric Dimethylarginine and Sympathetic Nerve Traffic after Renal Denervation in Patients with Resistant Hypertension. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1560-1567.	4.5	11

#	ARTICLE	IF	CITATIONS
145	Increased Risk of Bone Fractures in Hemodialysis Patients Treated with Proton Pump Inhibitors in Real World: Results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). <i>Journal of Bone and Mineral Research</i> , 2019, 34, 2238-2245.	2.8	11
146	Neuropeptide Y predicts cardiovascular events in chronic kidney disease patients. <i>Journal of Hypertension</i> , 2019, 37, 1359-1365.	0.5	10
147	An Additive Effect of Endothelial Nitric Oxide Synthase Gene Polymorphisms Contributes to the Severity of Atherosclerosis in Patients on Dialysis. <i>American Journal of Hypertension</i> , 2007, 20, 758-763.	2.0	9
148	Neuropeptide Y receptor Y2 gene polymorphism interacts with plasma neuropeptide Y levels in predicting left ventricular hypertrophy in dialysis patients. <i>Journal of Hypertension</i> , 2010, 28, 1745-1751.	0.5	9
149	Insulin resistance and left ventricular hypertrophy in end-stage renal disease: association between the ENPP1 gene and left ventricular concentric remodelling. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 661-666.	0.7	9
150	Long-Term Progression of Coronary Artery Calcification Is Independent of Classical Risk Factors, C-Reactive Protein, and Parathyroid Hormone in Renal Transplant Patients. <i>CardioRenal Medicine</i> , 2017, 7, 284-294.	1.9	9
151	Asymmetric dimethylarginine (ADMA) as a cardiovascular risk factor in end-stage renal disease (ESRD). <i>European Journal of Clinical Pharmacology</i> , 2006, 62, 131-135.	1.9	8
152	CARDIOVASCULAR AND SURVIVAL PARADOXES IN DIALYSIS PATIENTS: It Is Important to Lower Homocysteine in Dialysis Patients. <i>Seminars in Dialysis</i> , 2007, 20, 530-533.	1.3	8
153	Aldosterone, mortality, cardiovascular events and reverse epidemiology in end stage renal disease. <i>European Journal of Clinical Investigation</i> , 2015, 45, 1077-1086.	3.4	8
154	Circulating adiponectin modifies the FGF23 response to vitamin D receptor activation: a post hoc analysis of a double-blind, randomized clinical trial. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1764-1769.	0.7	8
155	FGF23 and the PTH response to paricalcitol in chronic kidney disease. <i>European Journal of Clinical Investigation</i> , 2020, 50, e13196.	3.4	8
156	Measures of Effect in Epidemiological Research. <i>Nephron Clinical Practice</i> , 2010, 115, c91-c93.	2.3	7
157	Aging and Left Ventricular Mass and Function in People with End-Stage Renal Disease. <i>Journal of the American Geriatrics Society</i> , 2011, 59, 1636-1641.	2.6	7
158	Comment accompanying: obstructive sleep apnoea: a stand-alone risk factor for chronic kidney disease by Chou Yu-Ting. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2072-2074.	0.7	7
159	Effect of Vitamin D Receptor Activation on the AGE/RAGE System and Myeloperoxidase in Chronic Kidney Disease Patients. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-7.	4.0	7
160	Lung ultrasound to detect and monitor pulmonary congestion in patients with acute kidney injury in nephrology wards: a pilot study. <i>Journal of Nephrology</i> , 2020, 33, 335-341.	2.0	7
161	Chronic Kidney Disease (CKD) as a Systemic Disease: Whole Body Autoregulation and Inter-Organ Cross-Talk. <i>Kidney and Blood Pressure Research</i> , 2014, 39, 134-141.	2.0	6
162	Physical exercise in haemodialysis patients: time to start. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1196-1198.	0.7	6

#	ARTICLE	IF	CITATIONS
163	The sirtuin1 gene associates with left ventricular myocardial hypertrophy and remodeling in two chronic kidney disease cohorts. <i>Journal of Hypertension</i> , 2018, 36, 1705-1711.	0.5	6
164	Vitamin D receptor activation raises soluble thrombomodulin levels in chronic kidney disease patients: a double blind, randomized trial. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 819-824.	0.7	6
165	Vitamin K and Kidney Transplantation. <i>Nutrients</i> , 2020, 12, 2717.	4.1	6
166	The Vessels-Bone Axis: Iliac Artery Calcifications, Vertebral Fractures and Vitamin K from VIKI Study. <i>Nutrients</i> , 2021, 13, 3567.	4.1	6
167	Soluble E-Selectin Is an Inverse and Independent Predictor of Left Ventricular Wall Thickness in End-Stage Renal Disease Patients. <i>Nephron Clinical Practice</i> , 2010, 114, c74-c80.	2.3	5
168	Salt and the heart in chronic kidney disease: an atrial connection. <i>Nephrology Dialysis Transplantation</i> , 2013, 28, 2210-2211.	0.7	5
169	Do we still need cross-sectional studies in Nephrology? Yes we do!. <i>Nephrology Dialysis Transplantation</i> , 2017, 32, gfw439.	0.7	5
170	Long-Term Changes in Sleep Disordered Breathing in Renal Transplant Patients: Relevance of the BMI. <i>Journal of Clinical Medicine</i> , 2020, 9, 1739.	2.4	5
171	Overweight-obesity is associated with decreased vitamin K2 levels in hemodialysis patients. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 581-589.	2.3	5
172	Prognostic models in the clinical arena. <i>Aging Clinical and Experimental Research</i> , 2012, 24, 300-304.	2.9	4
173	Norepinephrine, left ventricular disorders and volume excess in ESRD. <i>Journal of Nephrology</i> , 2015, 28, 729-737.	2.0	4
174	The dominant prognostic value of physical functioning among quality of life domains in end-stage kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2018, 35, 170-175.	0.7	4
175	Inflammation is an amplifier of lung congestion by high lv filling pressure in hemodialysis patients: a longitudinal study. <i>Journal of Nephrology</i> , 2020, 33, 583-590.	2.0	4
176	The Role of Vitamin K in CKD-MBD. <i>Current Osteoporosis Reports</i> , 2022, 20, 65.	3.6	4
177	Tissue inhibitor of metalloproteinases (TIMP-1), genetic markers of insulin resistance and cardiomyopathy in patients with kidney failure. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 2440-2445.	0.7	3
178	Vitamin D and methylarginines in chronic kidney disease (CKD). <i>PLoS ONE</i> , 2017, 12, e0185449.	2.5	3
179	Value of Troponin T as a Screening Test for Left Ventricular Hypertrophy in CKD. <i>American Journal of Kidney Diseases</i> , 2013, 61, 689-691.	1.9	2
180	Should we extend the application of more frequent dialysis schedules? A 'yes' and a hopeful 'no'. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 29-32.	0.7	2

#	ARTICLE	IF	CITATIONS
181	Physical functioning and mortality in very old patients on dialysis. Archives of Gerontology and Geriatrics, 2019, 85, 103918.	3.0	2
182	Prognostic Factors of Fatal and Nonfatal Cardiovascular Events in Patients With Type 2 Diabetes: The Role of Renal Function Biomarkers. Clinical Diabetes, 2021, 39, 188-196.	2.2	2
183	Mutual effect modification between adiponectin and HDL as risk factors of cardiovascular events in Type 2 diabetes individuals: a cohort study. International Urology and Nephrology, 2021, 53, 2583-2591.	1.4	2
184	Oral Calcitriol Use, Vertebral Fractures, and Vitamin K in Hemodialysis Patients: A Cross-Sectional Study. Journal of Bone and Mineral Research, 2020, 36, 2361-2370.	2.8	2
185	Guest Editor: Rajiv Agarwal: Cardiovascular Risk Profile Assessment and Medication Control Should Come First. Seminars in Dialysis, 2007, 20, 405-408.	1.3	1
186	Fluid overload and post-dialysis hypertension. Nature Reviews Nephrology, 2014, 10, 623-624.	9.6	1
187	Clinical Epidemiology of Systolic and Diastolic Orthostatic Hypotension in Patients on Peritoneal Dialysis. Journal of Clinical Medicine, 2021, 10, 3075.	2.4	1
188	Early morning hemodynamic changes and left ventricular hypertrophy and mortality in hemodialysis patients. Journal of Nephrology, 2022, , .	2.0	1
189	Is oxidative stress implicated in high bone turnover in end-stage renal disease (ESRD)?. Nephrology Dialysis Transplantation, 2006, 21, 1735-1736.	0.7	0
190	Vitamin K2 is a key regulator of clinically relevant molecular processes. , 2020, , 153-172.		0
191	Translational research in nephrology: prognosis. CKJ: Clinical Kidney Journal, 2022, 15, 205-212.	2.9	0